PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/00

A2

(11) International Publication Number: **WO 00/01375**

(43) International Publication Date: 13 January 2000 (13.01.00)

(21) International Application Number: PCT/CA99/00612

(22) International Filing Date: 30 June 1999 (30.06.99)

(30) Priority Data:
09/107,037 30 June 1998 (30.06.98) US

(71) Applicant *(for all designated States except US)*: NEUROMED TECHNOLOGIES, INC. [CA/CA]; Suite 400, 601 West Broadway, Vancouver, British Columbia V5Z 4C2 (CA).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: SNUTCH, Terrance, Preston [CA/CA]; 3963 W. 24th Avenue, Vancouver, British Columbia V6S 1M1 (CA). ZAMPONI, Gerald, Werner [CA/CA]; 99 Bernard Close N.W., Calgary, Alberta T3K 2H3 (CA).

(74) Agents: ROBINSON, J., Christopher et al.; Fetherstonhaugh & Co., Vancouver Centre, Suite 2200, Box 11560, 650 West Georgia Street, Vancouver, British Columbia V6B 4N8 (CA).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: CALCIUM CHANNEL BLOCKERS



(1)

(57) **Abstract**

Compounds of formula (1) wherein m is 0, 1 or 2; wherein when m is 0, Z is O; when m is 1, Z is N, and when m is 2, Z is C; Y is H, OH, NH_2, or an organic moiety of 1–20C, optionally additionally containing 1–8 heteroatoms selected from the group consisting of N, P, O, S and halo; each 1^1 and 1^2 is independently 0–5; 1^3 is 0 or 1; each of R^1, R^2 and R^3 is independently alkyl (1–6C), aryl (6–10C) or arylalkyl (7–16C) optionally containing 1–4 heteroatoms selected from the group consisting of halo, N, P, O, and S or each of R^1 and R^2 may independently be halo, COOR, $CONR_2$, CF_3, CN or NO_2, wherein R is H or lower alkyl (1–4C) or alkyl (1–6C); n is 0 or 1; X is a linker; with the proviso that Y is not a tropolone, a coumarin, or an antioxidant containing an aromatic group and with the further proviso that if 1^3 is 0, neither R^1 nor R^2 can represent F in the para position; and are useful as calcium channel blockers. Libraries of these compounds can also be used to identify antagonists for other targets.